Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Depreciation & Amortization (CF) (2016 - 2025)

KalVista Pharmaceuticals' Depreciation & Amortization (CF) history spans 10 years, with the latest figure at $220000.0 for Q2 2025.

  • For Q2 2025, Depreciation & Amortization (CF) changed 0.46% year-over-year to $220000.0; the TTM value through Apr 2025 reached $671000.0, down 17.77%, while the annual FY2025 figure was $900000.0, 10.29% up from the prior year.
  • Depreciation & Amortization (CF) for Q2 2025 was $220000.0 at KalVista Pharmaceuticals, down from $227000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $227000.0 in Q4 2024 and bottomed at $193000.0 in Q3 2023.
  • The 3-year median for Depreciation & Amortization (CF) is $219000.0 (2024), against an average of $212428.6.
  • The largest annual shift saw Depreciation & Amortization (CF) rose 16.06% in 2024 before it rose 0.46% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $197000.0 in 2023, then rose by 15.23% to $227000.0 in 2024, then decreased by 3.08% to $220000.0 in 2025.
  • Per Business Quant, the three most recent readings for KALV's Depreciation & Amortization (CF) are $220000.0 (Q2 2025), $227000.0 (Q4 2024), and $224000.0 (Q3 2024).